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Abstract:  
Synthetic cannabinoids have emerged as a dangerous new trend in illicit drug use. 
The appointment of many popular synthetic cannabinoids as Schedule I controlled 
substances has helped to decrease their popularity in recent years, but in order to enforce 
the new legislation, methods must be developed to detect the drugs in biological samples. 
The purpose of this study was to improve the detection of synthetic cannabinoids in 
urine. An LC-MS/MS method was developed to detect 14 synthetic cannabinoid parent 
compounds and metabolites, and THC. Comparison studies were performed to determine 
the conditions for the extraction of the target analytes via solid phase extraction (SPE).  
    
The suitability of three different SPE columns and three different eluents were 
analyzed during two different studies by extracting spiked urine samples and comparing 
the resulting peak areas. The effect of methanol wash solutions was analyzed by washing 
the columns with 30% methanol, 70% methanol, and 100% water solutions. A 10% 
acetonitrile reconstitution solution and 20% methanol reconstitution solution were 
compared to determine which was better suited for the recovery of the target analytes. 
Finally, linearity, carryover, and matrix effects validation studies were performed on the 
final method. 
   
The column and elution comparison studies revealed that the SPEware CEREX® 
HP SAX 5 mg NBE column paired with a DCM:IPA:NH4OH elution performed best for 
the target analytes. The methanol wash study showed that high methanol content in the 
wash solvent resulted in analyte loss during extraction. The 100% water wash was 
determined to be most favorable for the extraction of synthetic cannabinoids. The 20% 
methanol solution greatly improved the recovery of all analytes. The calibration curve 
included a 1c, 2c, 5c, 10c, 15c, and 25c for all analytes except THC which did not use a 
1c calibrator. The linearity study showed that linear calibration models worked for some 
analytes, while others required a quadratic fit model. No carryover was observed at the 
upper limit of quantitation. Matrix effects ranged between 64% and 270%. Recovery 
efficiencies were 12-158%, and process efficiencies were 12-417%.   
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CHAPTER I 
 
 
INTRODUCTION 
 Synthetic cannabinoids, commonly known as Spice or K2, are compounds 
originally developed to study the effects of marijuana. The drug class consists of 
hundreds of structurally similar compounds that are anything but safe. In 2011 the use of 
synthetic cannabinoids resulted in more than 28,500 emergency room visits in the United 
States.1 During the same year, synthetic cannabinoids were the second most abused drugs 
among 12th graders. As of 2014, the overall use of synthetic cannabinoids has decreased 
but they still ranks as the third most abused drugs for 8th, 10th, and 12th graders.2,3 
 Despite the alarming number of emergency room visits due to synthetic 
cannabinoid use, surveys show that the perceived risk of synthetic cannabinoids is low.2,3 
Considering the low perceived risk, health concerns are unlikely to be the cause of 
decreased use. One likely deterrent is the illegalization of many popular synthetic 
cannabinoid compounds. Currently, the Drug Enforcement Administration (DEA) has 
permanently or temporarily added several of the most popular synthetic cannabinoids to 
the list of Schedule I Controlled Substances. According to the DEA, “Substances in this 
schedule have no currently accepted medical use in the United States, a lack of accepted 
safety for use under medical supervision, and a high potential for abuse.”4 Unfortunately  
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with so many different synthetic cannabinoids available for synthesis, enforcing the ban 
is difficult.  
Currently, few comprehensive drug screens include synthetic cannabinoids. Those 
that do usually test for only a few of the first synthetic cannabinoids banned by the DEA 
in 2011. The lack of standard testing for synthetic cannabinoids is a major reason for the 
continued popularity among adolescents.5 Thus, improving testing techniques for 
synthetic cannabinoids is an important area of study. Increased ability to detect synthetic 
cannabinoids in biological samples is beneficial both clinically and forensically. 
Clinically, a comprehensive test for popular synthetic cannabinoids would aid doctors in 
diagnosing synthetic cannabinoid exposure, which then would improve the ability to treat 
the patient. Forensically, comprehensive testing for illegal synthetic cannabinoids would 
increase the likelihood that use would result in punishment, which would decrease the 
popularity of the drug.  
 Synthetic cannabinoids can be detected in many biological samples; but the 
sample types most commonly tested are urine,6–9 serum, or whole blood.9–12 The 
synthetic cannabinoid parent drugs are excreted in very low concentrations in the urine. 
For this reason, urine drug screens rely on the detection of synthetic cannabinoid 
metabolites rather than the parent drug.12 The detection of a parent drug is preferable and 
can be done by testing serum or blood; however, the collection of blood and serum is 
much more invasive than the collection of urine. The non-invasiveness of urine samples 
makes it a popular sample for clinical, forensic, and work-place drug testing. 
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 Before a sample can be tested for the presence of synthetic cannabinoid, it must 
undergo sample preparation. There are two techniques most commonly used to prepare 
samples for synthetic cannabinoids detection: liquid-liquid extraction (LLE)6,10–12 and 
solid-phase extraction (SPE).7,9 Both techniques are sufficient for sample preparation but 
also have weaknesses. LLE works well for the extraction of hydrophobic compounds like 
synthetic cannabinoids but requires large volumes of harmful chemicals. SPE is less 
favorable for synthetic cannabinoid extraction but requires smaller volumes of both 
sample and solvent.13 
 A third option for sample preparation is supported-liquid extraction (SLE). SLE 
combines techniques from LLE and SPE to create a technique that requires small 
volumes of sample and solvent yet still works well for hydrophobic compounds.13 One 
study7 provides supplementary data that suggest SLE does provide an improved sample 
preparation for synthetic cannabinoid detection; however, the sample size was small and 
the difference in extraction efficiencies was not tested for significance. 
 The purpose of this study was to develop an efficient solid phase extraction (SPE) 
method for the extraction of several illegal synthetic cannabinoids, Δ9-THC, and THCA 
and analyze the spiked samples via a liquid chromatography and tandem mass 
spectrometry (LC-MS/MS) method developed specifically for the analysis of synthetic 
cannabinoids. The SPE method was developed by analyzing the effects of changing 
variables such as SPE column type and solvents used for washes, elution, and 
reconstitution. Finally, the validity of the method was analyzed by performing linearity, 
carryover, and matrix effects studies.   
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If, as hypothesized, current SPE methods can be improved significantly for the 
extraction of synthetic cannabinoids, the newly applied method has potential to improve 
current testing methods for active drug testing laboratories. Furthermore, the technique 
may aid in further decreasing the popularity of synthetic cannabinoid by providing 
information that can be used to enforce the current legislation banning popular synthetic 
cannabinoids. 
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
Introduction 
 Synthetic cannabinoids are compounds that were synthetized due to their 
structural or functional similarity to the “natural” cannabinoids such as delta-9-
tetrahydrocannabinol (Δ9-THC), the main psychoactive chemical in marijuana. The 
original use of most synthetic cannabinoids was to research the mechanisms of the 
cannabinoid system or to study the possible therapeutic uses of both natural and synthetic 
cannabinoids.14,15 Cannabinoid research resulted in the development and publication of 
hundreds of different synthetic cannabinoid compounds. Years later, the publications 
became guides for the manufacture of recreational synthetic cannabinoids. The 
emergence of recreational synthetic cannabinoids began as early as 2004 and they 
steadily gained popularity due to the “legal high” promised to users.15,16 Since then, new 
synthetic cannabinoids with various chemical structures have been produced and 
subsequently outlawed. However, comprehensive detection methods for the illegal 
synthetic cannabinoids in biological samples still need to be developed and improved. 
Production and Marketing 
 Research suggests that production of recreational synthetic cannabinoids began in 
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Asian countries, China in particular. The synthetic cannabinoids are synthesized and 
purified into a powder. The powder is then shipped in bulk to other countries using legal 
trade routes. The powder can then be used in a few different ways. The most common 
 preparation for synthetic cannabinoids is to add them to a mixture of dried plant material, 
often labeled as an herbal blend. The combination of the synthetic cannabinoids and plant 
material is more commonly referred to as Spice; although, Spice is only one of several 
popular brands of synthetic cannabinoids product.15–18 The plants used in Spice blends 
are generally inert, but some may be chosen for their reported psychoactive effects. 
However, psychoactive effects caused by the plants are weak and outweighed by the 
much stronger effects of the synthetic cannabinoids.19 
 In the production of Spice, solvents such as methanol or acetone can be used to 
dissolve the powder before it is sprayed onto a mixture of inert herbs. Spraying the herbs 
is done on an industrial scale in order to speed the production. The herbs are allowed to 
dry before they are packaged.17 Spice is normally packaged in quantities between 0.4g 
and 3g.19 The information included on the Spice packaging is often misleading. 
Packaging may fail to include the synthetic cannabinoids in the ingredients list, may 
include statements such as “not for human consumption,” or by fail to state that the 
synthetic cannabinoids previously used in the product have changed.15,16,20 Additionally, 
the packaging of some Spice products will inform the buyer which illegal synthetic 
cannabinoids are not included in the product.15 
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Spice is most often burned in rolled cigarette papers, pipes, or water pipes so it 
can be inhaled. Spice may also be ingested, but ingestion is less common and results in 
weaker effects than inhalation.  
Synthetic cannabinoids can be purchased in forms other than the Spice blend. It is 
also possible to purchase synthetic cannabinoids in powdered form, but the product may 
be difficult to find. Because the powder is a more pure form of synthetic cannabinoids, 
ingestion of the powder produces a stronger effect than ingestion of Spice. The powder 
can be easily mixed into alcoholic drinks or with other drugs resulting in an increased 
risk of toxicity due to multiple drug interactions. There is at least one report of a user 
requiring medical attention after mixing synthetic cannabinoid powder in an alcoholic 
beverage.21 Powdered synthetic cannabinoids may also be dissolved in liquid propellants 
commonly used for electronic cigarettes (e-cigs). The liquid product can then be 
vaporized and inhaled when used in conjunction with e-cigs.14 
Legislation 
 The initial popularity of synthetic cannabinoids as a recreation drug was due to a 
lack of legislation banning their production, sale, and use. Before synthetic cannabinoids 
could be made illegal, the structure of the compound had to be determined. The first 
detection of synthetic cannabinoids in seized samples occurred in late 2008 in Europe14,17 
and the United States.14 The first synthetic cannabinoid detected was JWH-018, 1-
naphthalenyl(1-pentyl-1H-indole-3yl)methanone.17,19,22 Soon after, JWH-018 and other 
popular synthetic cannabinoids were made illegal by many legislatures. In the United 
States JWH-018, JWH-073, JWH-200, CP-47,497, and the CP-47,497 C8 homologue 
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were temporarily placed on the Schedule I substances list on March 1, 2011.14,23 On July 
9, 2012, those synthetic cannabinoids were permanently added as Schedule I 
substances.14 
 At the time the first synthetic cannabinoid legislation was passed, most drugs 
were banned based on their unique chemical structure. This type of legislation does not 
allow for the automatic scheduling of structurally similar substances. As a result, new 
structurally similar synthetic cannabinoids gained popularity after the legislation was 
passed against the first synthetic cannabinoids.24 There were no legal consequences for 
using the new structurally similar compounds, so synthetic cannabinoids maintained their 
popularity as a legal high. Finally, some legislatures enacted “homologue laws.” The 
homologue laws automatically prohibit compounds that are very structurally similar to 
previously prohibited compounds.18 
Trends 
When synthetic cannabinoids first gained popularity, they were used by a large 
demographic range. However, several studies show that synthetic cannabinoids are 
currently used primarily by teens and young adults. According to the 2014 Monitoring 
the Future Survey,5 synthetic cannabinoids are the third most highly abused drugs among 
8th, 10th, and 12th graders, although marijuana is the most frequently abused substance for 
all three age groups. The survey also indicates a decrease in the overall frequency of 
synthetic cannabinoid use for 10th and 12th graders between 2012 and 2014. For 12th 
graders, the self-reported synthetic cannabinoid use dropped from 11.3% in 2012 to 5.8% 
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in 2014. For 10th graders, the use dropped from 8.8% in 2012 to 5.4% in 2014. However, 
the use of synthetic cannabinoids among 8th graders has not significantly decreased.2,3 
 Despite the apparent decrease in synthetic cannabinoid use, new synthetic 
cannabinoid compounds continue to be produced. Two of the newest class of synthetic 
cannabinoids to hit the market, AB-PINACA and AB-FUBINACA, are commonly sold 
in liquid form for use with e-cigarettes. Other new synthetic cannabinoids, such as MAB-
CHMINACA and ADB-CHMINACA, reportedly have severe side-effects that send many 
users to the hospital.25 
Pharmacodynamics and Pharmacokinetics 
Synthetic cannabinoids affect Cannabinoid Receptor 1 (CB1) and Cannabinoid 
Receptor 2 (CB2), which are both part of the cannabinoid system. CB1 and CB2 are also 
affected by Δ9-THC. For this reason, synthetic cannabinoids are reported to produce a 
“cannabis-like” high. However, many synthetic cannabinoids have the potential to bind 
much more strongly to the CB receptors. As a result, a stronger positive effects can be 
achieved with a smaller dose. Likewise, toxic effects are also amplified, even with small 
doses.20,22    
Not only are the strength of synthetic cannabinoid effects unpredictable, but the 
nature of the effects are also unpredictable. For example, one user may present to the 
hospital with tachycardia (rapid heartbeat) and dilated pupils, while a second user may 
suffer from bradycardia (slow heartbeat) and constricted pupils.15,26 
Much research still needs to be completed regarding the absorption, distribution, 
metabolism, and excretion of synthetic cannabinoids. However, there have been some 
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studies that provide valuable information about the pharmacokinetics of certain synthetic 
cannabinoid compounds. A 2012 study6 administered a 0.15 g of a synthetic cannabinoid 
product to an individual and monitored the resulting concentration of drug metabolites in 
individual’s urine over a period of 65 hours. The results of this study showed a detection 
window of the synthetic cannabinoid metabolites for 2-3 days in urine with a limit of 
quantitation around 0.1 ng/mL, with maximum concentration around 10 ng/mL at 1-3 
hours post-administration. 
In another study, Gurney, et al27, collected case reports and quantitative results for 
synthetic cannabinoids in urine, whole blood and serum. In blood, levels as low as 0.2 
ng/mL were detected. In urine, metabolite concentrations were as low as 0.03 ng/mL. The 
concentration of synthetic cannabinoid detected varied between individuals and different 
synthetic cannabinoid compounds. A third study28 included the quantification of 862 
synthetic cannabinoid positive cases. In whole blood concentration ranged between about 
0.05 ng/mL and about 68 ng/mL.  
Chromatography and Detection Methods 
Proper chromatographic separation of structurally similar compounds is very 
important for the detection of synthetic cannabinoids. Chromatography separation of 
cannabinoids in biological samples is most often completed via either Gas 
Chromatography (GC) or Liquid Chromatography (LC). The chromatographic separation 
is then followed by detection via Mass Spectrometry (MS).29,30 The analysis of synthetic 
cannabinoids by GC-MS is complicated by the structural similarity of synthetic 
cannabinoid parent and metabolite structures and fragmentation which makes selective 
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identification difficult. Finally, the thermal-instability of some synthetic cannabinoids 
makes their detection by GC-MS impossible in most cases.30  
Unlike most GC-MS methods, LC-MS methods are able to separate and identify 
structurally similar synthetic cannabinoids and their metabolites. Detection of metabolites 
is particularly important for the development of a method to detect synthetic 
cannabinoids in urine because the parent compounds of many synthetic cannabinoids are 
not excreted in urine.31 These advantages of LC-MS over GC-MS methods are why LC-
MS is most commonly used for the analysis of synthetic cannabinoids in biological 
samples.30  
Sample Extraction 
Both natural and synthetic cannabinoids are usually prepared for detection by 
either a liquid-liquid extraction (LLE) or solid-phase extraction (SPE).30 LLE is favorable 
for synthetic cannabinoid extraction due to the hydrophobicity of the compounds. 
Kacinko et al11 used a LLE method for the extraction of JWH-018, JWH-073, JWH-019, 
and JWH-250 from whole blood. The reported recovery efficiency for the method was 
between 60.6% and 92.8% for all analytes and met all validation requirements. However, 
the recovery efficiency may be negatively impacted when more synthetic cannabinoids 
are included in the extraction method. Kneisel and Auwärter12 used a LLE technique for 
the detection of 30 synthetic cannabinoids in serum, but the recovery efficiencies ranged 
between 5.7% - 56%. These recoveries were much lower than the recovery of Kacinko’s 
less inclusive method. Another downfall of LLE is the need for large volumes of odorous 
or carcinogenic solvents.  
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SPE is a more complex extraction process than LLE, but the use of extraction 
columns requires a smaller volume of solvent and the solvents are usually less toxic.13 
SPE methods can also have recovery efficiencies comparable to or better than the 
recovery efficiencies of LLE methods. Erol Öztürk, et al9 used a SPE preparation for the 
LC-MS/MS analysis of JWH-018 and two of its metabolites in blood and urine with 
recovery efficiencies of 87–98% and 85–96%. Sundström, et al32 developed a ultra-high 
performance liquid chromatography/high-resolution time-of-flight mass spectrometry 
(UHPLC-HR-TOFMS) method to detect several illicit drugs including 54 synthetic 
cannabinoid analytes and THCA. The recovery efficiency if the method was between 
46% and 82% except for HU-210 which had a recovery efficiency of 27%. 
Recently there has been a gain in popularity of the supported liquid extraction 
(SLE) technique. SLE uses techniques from both LLE and SPE. Using SLE can increase 
the extraction efficiency.13 Currently there is very little literature available on the use of 
SLE for urine cannabinoid methods. One study7 successfully used SLE for the extraction 
of natural cannabinoids from urine. A 2014 study by Scheidweiler and Huestis7 
successfully used SLE for the extraction of synthetic cannabinoids in urine. In the 2014 
synthetic cannabinoids study, preliminary data were gathered on the extraction efficiency 
of SLE compared to SPE, and showed that SLE was better suited for the extraction of 
parent synthetic cannabinoids than SPE. The comparison study included a very small 
sample size of two parent synthetic cannabinoids and two metabolites, but the SLE 
method was able to successfully extract 53 synthetic cannabinoid analytes with recovery 
efficiencies between 43.7% and 109.3%. Although SLE shows potential for an efficient 
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extraction of synthetic cannabinoids, it is not an extraction method that is currently 
available to most labs. 
Conclusion 
 The literature shows that synthetic cannabinoids pose a significant health risk. 
Despite the health risks, they continue to be popular drugs of choice for teens. One way 
to further decrease the popularity of synthetic cannabinoids is to improve the detection 
methods for biological samples. SPE is an extraction method that is cleaner than simple 
dilution methods, produces less waste than LLE methods, and is more readily available 
than SLE methods. Additionally, SPE has been shown to successfully extract synthetic 
cannabinoids from urine in the past. Therefore, maximizing synthetic cannabinoid 
recovery from a SPE extraction method is a bases for further research in improving 
synthetic cannabinoid detection.  
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CHAPTER III 
 
 
METHODOLOGY 
Overview 
 The purpose of this study was to develop a liquid chromatography and tandem 
mass spectrometry (LC-MS/MS) method to detect several synthetic cannabinoids in urine 
and to use that detection method to evaluate the of effects of altering variables of a solid 
phase extraction (SPE) method. The variables examined in this study include SPE 
column type, elution solvent used, solutions used for washing the column, and solution 
used for reconstitution.  
 In this study, blank urine samples were spiked with a known concentration of 
drug standard. The urine used in this study contained no personal identifying information. 
The spiked blank urine was then extracted via various SPE methods and analyzed by LC-
MS/MS. The recovery of drug from urine was determined by comparing peak areas or 
concentration and used to compare the extraction efficiency of each extraction. The most 
efficient variable from each method was then combined into a final SPE method that was 
used for validation studies.  
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Materials 
 The materials required for this study include drug standards, drug-free urine, 
reagents, and solid phase extraction (SPE) columns. The drug standards used in this study 
were obtained from Cerilliant. The certified drug-free urine was purchased from UTAK. 
Reagents, laboratory grade or higher, were purchased from VWR International. The SPE 
columns used were CEREX® HP SAX 5 mg NBE, CEREX® HP SAX 2.5 mg NBE, and 
CEREX® HP SCX 5 mg NBE extraction columns which were purchased from SPEware 
Corporation.  
Liquid Chromatography and Tandem Mass Spectrometry 
The LC-MS/MS Shimadzu 8040 shown in Figure 1 was used to analyze samples 
extracted via SPE. Lab Solutions software was used to remotely control the LC-MS. The 
column that was used for analysis is the Raptor™ Biphenyl with 50 mm x 3.0 mm 
dimensions and 2.7 µm particle size. The guard column used to protect the column was 
the Raptor™ Biphenyl EXP® with 5 mm x 3.0 mm dimensions and 2.7 µm particle size. 
Both the column and guard column were obtained from Restek Corporation. 
 
Figure 1. LC-MS/MS Shimadzu 8040 used in this study. 
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The chromatographic conditions were determined with the use of standard and 
internal standard mixes prepared in water to determine which conditions provide the best 
peak shape and separation. The conditions used by Restek Corporation33 for the testing of 
the Raptor™ Biphenyl column were be used as a starting point. The final 
chromatography method utilized mobile phase A (MPA) consisting of 2mM ammonium 
formate and 0.1% formic acid in water. Mobile phase B (MPB) consisted of 0.1% formic 
acid in 9:1 acetonitrile:water. The mobile phase gradient is detailed in Figure 2. 
      
The mass spectrometer (MS) was run in positive mode and with electrospray 
ionization (ESI). Each drug and internal standard was optimized for detection using Lab 
Solutions’ auto-optimization feature. The optimizations were manually adjusted as 
needed. Lab Solutions will also be used to collect and analyze the generated data. 
Solid Phase Extraction Methods 
The SPE extractions were carried out on the SPEware ALD device shown in 
Figure 3. For this study, two previously developed SPE methods were used. The first 
Figure 2. Mobile phase B concentration gradient for the LC method 
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method was an SPE method for synthetic cannabinoids in urine provided by SPEware. 
The method, described below, will be referred to as the SPEware method in this paper. 
The second method was a SPE method developed for the extraction of pain management, 
illicit, and other prescription drugs from urine provided by the Forensic Toxicology and 
Trace Laboratory at OSU-CHS. The method, described below, will be referred to as the 
FTTL method in this paper. Variables from each method were adjusted individually to 
determine the change in extraction efficiency, if any, for each variable. The variables 
analyzed were column bed depth, elution solvent composition, column ion affinity, wash 
solvent composition, and reconstitution solvent composition. 
   SPEware Solid Phase Extraction 
For the SPEware sample preparation procedure, hydrolysis solution was prepared 
daily by combining 200 µL of 100 mM sodium acetate buffer (pH 5.0), 15 µL of β-
glucuronidase solution, and 10 µL of internal standard stock solution per sample. Then 
225 µL of hydrolysis solution and 200 µL of spiked urine were added to a CEREX® HP 
SAX 5 mg NBE column. The sample was mixed by repeated aspiration/dispense of a 
micropipette. The columns were then covered with aluminum foil and placed in a 68°C 
incubator for 30 minutes. After the incubation, the samples were cooled to room 
temperature before proceeding with the SPE method. 
 Samples were applied to the columns at a flow rate of 0.5 – 1 mL/minute. The 
columns were then washed with 0.5 mL of a 85:15:1 mixture of deionized water, 
acetonitrile, and ammonium hydroxide (H2O:ACN:NH4OH) at a flow rate of 0.5 – 1 
mL/minute. The H2O:ACN:NH4OH wash was prepared each day before extraction. Next, 
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the columns were washed with 0.5 mL of a 70% methanol (MeOH) solution at a flow rate 
of 0.5 – 1 mL/minute. The columns were dried under 70 psi nitrogen for 10 minutes. The 
analytes were eluted with 200 µL of 98:2 ethyl acetate and formic acid (EtOAc:FA) and 
collected in a 1 mL 96-well plate at 0.5 – 1 mL/minute. The samples were evaporated to 
dryness under nitrogen for 20 minutes and reconstituted with 100 µl of MPA:MPB (9:1).  
FTTL Solid Phase Extraction 
Hydrolysis solution was prepared daily with 350 µL of 0.3 M sodium acetate 
buffer (pH 4.8), 10 µL of β-glucuronidase solution, and 10 µL of internal standard stock 
solution per sample. Then 370 µL of hydrolysis solution and 200 µL of spiked urine were 
added to a CEREX® HP SCX 5 mg NBE column. The samples were mixed by 
performing repeated aspiration/dispense steps. The columns were then placed in a 68°C 
incubator for 30 minutes. After incubation the samples were cooled to room temperature. 
 The samples were applied to the column at a flow rate of 0.5 – 1 mL/minute. The 
columns were then washed with 600 µL of H2O, then 200 µL of 100 mM HCl, and 
finally 300 µL of H2O. All three washes were applied at a flow rate of 0.5 – 1 mL/ 
minute. The columns were dried under nitrogen at 70 psi for 15 minutes. The analytes 
were eluted with 400 µL of 80:18:2 dichloromethane, isopropanol, and ammonium 
hydroxide (DCM:IPA:NH4OH). Samples were collected in a 1 mL 96-well plate and 
evaporated to dryness under nitrogen. The samples were then reconstituted with 100 µL 
of 20% MeOH.    
Column Bed and Elution Solvents 
To test the effect of column depth and variation of elution on extraction 
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efficiency, four urine curves were extracted simultaneously with two different columns 
and two different elution solvents. Curve A was extracted according to SPEware method 
with the CEREX® HP SAX 5 mg NBE column and a EtOAc:FA (98:2) elution. Curve B 
was extracted according to the SPEware method with CEREX® HP SAX 5 mg NBE 
column, however, the elution solvent was replaced with 200 µL of an 80:18:2 
dichloromethane, isopropanol, and formic acid (DCM:IPA:FA). Curve C was extracted 
using the CEREX® HP SAX 2.5 mg NBE column and EtOAc:FA (98:2) elution. Curve 
D was extracted using the CEREX® HP SAX 2.5 mg NBE column and DCM:IPA:FA 
(80:18:2) elution.  
   The curves for this portion of the study were prepared by a serial dilution of a 5 
µg/mL stock solution, shown in Table 1. Each curve included ten samples: 1 ng/mL, 2 
ng/mL, 5 ng/mL, 10 ng/mL, 20 ng/mL, 50 ng/mL, 100 ng/mL, 250 ng/mL, 500 ng/mL, 
and blank. The internal standard solution consisted of 7 deuterated internal standard. 
Deuterated internal standards were not available for all analytes, so the appropriate 
internal standard was chosen based on structural similarities. The internal standard groups 
are shown in Table 1.  
The peak areas for each analyte were recorded and compared between the four 
curves to determine which column bed depth and elution solvent combination was most 
efficient for the extraction of the analytes. The peak shape and area for each analyte were 
used to determine the likely limits of detection (LODs) and limits of quantitation (LOQs) 
for each analyte in the method. 
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Water to Methanol Ratio in Wash 
 The next step in the study was to analyze the effect of altering the methanol 
(MeOH) content of the second SPE wash step. Six 500 ng/mL urine samples were 
prepared from the 5 µg/mL stock solution listed in Table 1. Three samples were extracted 
with the CEREX® HP SAX 5 mg NBE column and each was washed with 0.5 mL of 
70% MeOH, 30% MeOH, or 100% H2O during the second wash step. The other three 
samples were extracted with the CEREX® HP SAX 2.5 mg NBE extraction column and 
were washed with 0.5 mL of 70% MeOH, 30% MeOH, or 100% H2O during the second 
wash step. Excluding the column and MeOH wash changes, the extraction was performed 
according the SPEware SPE procedure. The peak areas for each sample were compared 
to determine which wash resulted in the best recovery of all the analytes. 
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Column Ion Affinity and Eluent pH 
The 5 µg/mL curve stock listed in Table 1 was used to spike eight, 500 ng/mL 
urine samples. Four of the samples were prepared according to the SPEware sample 
preparation method, and four of the samples were prepared according to the FTTL 
sample preparation method. Two samples from each sample preparation were added to a 
CEREX® HP SAX 5 mg NBE column, and two from each were added a CEREX® HP 
SCX 5 mg NBE column. The FTTL extraction procedure was followed until the elution 
Table	1.	List	of	analytes	and	their	concentration	in	the	first	standard	stock	mix	and	internal	
standard	stock	mix	
Analyte	 Concentration	(ug/mL)	
Internal	Standard	
Group	
Standards	 	 	
5-Fluoro	PB-22	 5	 4	
AB-FUBINACA	 5	 3	
AM2201	4-Hydroxypentyl	metabolite	 5	 1	
HU-210	 5	 6	
JWH-018	Metabolite	 5	 2	
JWH-019	5-Hydroxyheyxyl	metabolite	 5	 2	
JWH-073	Metabolite	 5	 2	
JWH-122	5-Hydroxypentyl	metabolite	 5	 3	
JWH-250	5-Hydroxypentyl	 5	 4	
PB-22	 5	 4	
THC	 5	 5	
THCA	 5	 6	
UR-144	 5	 7	
UR-144	5-Hydroxypentyl	metabolite	 5	 7	
XLR-11	 5	 7	
XLR-11	4-Hydroxypentyl	metabolite	 5	 7	
Internal	Standards	 	 	
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 1	 1	
IS	JWH-018	Metabolite-D5	 1	 2	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 1	 3	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 1	 4	
IS	THC-D3	 10	 5	
IS	THCA-D3	 10	 6	
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 1	 7	
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step, at which point one sample from each column type was eluted with 400 µL of 
DCM:IPA:NH4OH (80:18:2), and the other sample from each column type was eluted 
with 400 µL of DCM:IPA:FA (80:18:2). This process is diagramed in Figure 4. All 
samples were the evaporated to dryness and reconstituted in 100 µL MPA:MPB (9:1). 
 
Reconstitution Solvent 
 Six 500 ng/mL urine samples were prepared from the 5 µg/mL standard stock 
solution listed in Table 1. The six urine samples were extracted according to the FTTL 
sample preparation and SPE methods using the CEREX® HP SAX 5 mg NBE column. 
Three of the samples were reconstituted with 100 µL of MPA:MPB (9:1), and three 
samples were reconstituted with 100 µL of 20% MeOH solution. Additionally, in effort 
to improve the detection of THCA, two urine samples spike at 500 ng/mL THCA were 
Figure	3.	Diagram	of	the	altered	variables	for	the	analysis	of	column	ion	affinity	
and	eluent	pH	effect	on	synthetic	cannabinoid	extractions.		
Urine	Samples
SPEware	Sample	
Preparations
HP	SAX
DCM:IPA:FA
DCM:IPA:NH4OH
HPSCX
DCM:IPA:FA
DCM:IPA:NH4OH
FTTL	Samples	
Preparations
HPSAX
DCM:IPA:FA
DCM:IPA:NH4OH
HPSCX
DCM:IPA:FA
DCM:IPA:NH4OH
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extracted following the same procedure. The analyte peak areas for each reconstitution 
were averaged and the standard deviation was determined.  
Final Solid Phase Extraction Method 
 The final SPE method was determined after reviewing the data from each variable 
study to determine the overall best procedure for extracting the synthetic cannabinoid and 
THC analytes from urine. The LOD and LOQ for each analyte were set at this time. For 
the purposes of this study, the LOD and LOQ were the same for each respective analyte, 
and any peak below the LOQ was considered a negative result. The LOQ for each analyte 
is shown in Table 2.  
 Sample preparation for the final method followed the FTTL sample preparation 
procedure. Hydrolysis solution containing 350 µL of 0.3 M sodium acetate buffer (pH 
4.8), 10 µL of β-glucuronidase solution, and 10 µL of IS standard stock solution (shown 
in Table 3) per sample was prepared for each extraction. For each sample, 370 µL of 
hydrolysis solution was combined with 200 µL of urine in a CEREX® HP SAX 5 mg 
NBE column. The solutions were mixed by repeated aspiration/dispense steps. The 
columns were incubated at 68°C for 30 minutes. After incubation, the samples were 
cooled to room temperature.  
The samples were applied to the column at a flow rate of 0.5 – 1 mL/minute. The 
columns were then washed with 600 µL of H2O, followed by 200 µL of 100 mM HCl, 
and finally 300 µL of H2O. Each wash was applied at a flow rate of 0.5 – 1 mL/minute. 
The columns were dried under nitrogen at 70 psi for 15 minutes. The analytes were eluted 
off the column with 400 µL of DCM:IPA:NH4OH (80:18:2) and collected in a 1 mL 96-
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well plate and evaporated to dryness under nitrogen. Finally, the samples were 
reconstituted with 100 µL of 20% MeOH. 
 
 
 
 
 
 
 
 
 
Table	2.	Limit	of	quantitation	for	analytes	included	in	the	final	SPE	and	LC-MS/MS	methods.	
Analyte	 LOQ	(ng/mL)	
5-Fluoro	PB-22	 1	
AB-FUBINACA	 1	
AM2201	4-Hydroxypentyl	metabolite	 1	
HU-210	 400	
JWH-018	Metabolite	 1	
JWH-019	5-Hydroxyheyxyl	metabolite	 1	
JWH-073	Metabolite	 1	
JWH-122	5-Hydroxypentyl	metabolite	 1	
JWH-250	5-Hydroxypentyl	 2	
PB-22	 1	
THC	 200	
UR-144	 2	
UR-144	5-Hydroxypentyl	metabolite	 2	
XLR-11	 2	
XLR-11	4-Hydroxypentyl	metabolite	 2	
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Linearity and Carryover 
 Linearity and carryover were accessed by extracting six, six-point calibration 
curves consisting of a 1c, 2c, 5c, 10c, 15c, 25c, and Blank sample. The 1c for each 
analyte was the LOQ concentration listed in Table 3, except for THC with an LOQ 
corresponding to the 2c calibrator. The calibration curves were prepared by serial dilution 
of a blank urine sample spiked with the 250c stock solution shown in Table 3. The 
calibrators and blank samples were then extracted according to the fine SPE method 
procedure. Calibration curves were analyzed from 1c to 25c with the blank sample 
Table	3.	List	of	analytes	and	their	concentration	in	the	standard	and	internal	standard	stock	
mixes	for	the	final	SPE	and	LC-MS/MS	method.		
Analyte	 Concentration	(ug/mL)	
Internal	Standard	
Group	
Standards	 	  
5-Fluoro	PB-22	 0.25	 4	
AB-FUBINACA	 0.25	 3	
AM2201	4-Hydroxypentyl	metabolite	 0.25	 1	
HU-210	 50	 5	
JWH-018	Metabolite	 0.25	 2	
JWH-019	5-Hydroxyheyxyl	metabolite	 0.25	 2	
JWH-073	Metabolite	 0.25	 2	
JWH-122	5-Hydroxypentyl	metabolite	 0.25	 3	
JWH-250	5-Hydroxypentyl	 0.5	 4	
PB-22	 0.25	 4	
THC	 25	 5	
UR-144	 0.5	 6	
UR-144	5-Hydroxypentyl	metabolite	 0.5	 6	
XLR-11	 0.5	 6	
XLR-11	4-Hydroxypentyl	metabolite	 0.5	 6	
Internal	Standards	 	  
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 1	 1	
IS	JWH-018	Metabolite-D5	 1	 2	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 1	 3	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 1	 4	
IS	THC-D3	 10	 5	
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 1	 6	
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following the 25c in order to access carryover from the highest concentration included in 
the method. Lab Solutions software was used to determine the best fitting line and 
weighting for each analyte. 
Matrix Effects 
 Matrix effects were evaluated by analyzing two neat urine samples, five post-
extraction spiked urine samples, and five pre-extraction spike urine samples. The neat 
urine samples were prepared by combining 2 µL of 250c standard stock solution, 10 µL 
of internal standard solution, and 88 µL of 20% MeOH in the well of a 1 mL 96-well 
plate. The first neat urine sample was injected three times, and the second neat urine 
sample was injected two time to make a total of five neat urine sample analyses.  
 The post-extraction spiked samples were prepared by adding 200 µL of blank 
urine to a CEREX® HP SAX 5 mg NBE column. All five blank samples were from a 
different individual. Next 370 µL of modified hydrolysis solution was added to each 
sample. The modified hydrolysis solution consisted of 350 µL of 0.3 M sodium acetate 
buffer (pH 4.8), 10 µL of MeOH, and 10 µL of H2O per sample. The samples were then 
extracted according to the final SPE method through the sample evaporation to dryness 
step. Finally, the samples were reconstituted with 2 µL of 250c standard stock solution, 
10 µL of internal standard solution, and 88 µL of 20% MeOH. Each sample was injected 
once. 
 The pre-extraction spiked samples were prepared by adding 2 µL of 250c 
standard stock solution and 200 µL of blank urine samples from five different individuals 
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to CEREX® HP SAX 5 mg NBE columns. The samples were then extracted according to 
the final SPE method and inject once. 
 The Matrix Effect (ME) was calculated by dividing the average peak area of the 
post-extraction urine samples by the peak area of the average peak area of the neat 
solution samples and multiplying the result by 100. This value is expressed as a 
percentage. The Recovery Efficiency (RE) was determined by dividing the average of the 
pre-extraction spike samples by the average of the post-extraction spike samples and 
multiplying by 100. The RE is also expressed as a percentage. Process Efficiency (PE) 
was determined by dividing the average of the pre-extraction spike samples by the 
average of the neat samples and multiplying by 100. The PE is also expressed as a 
percentage.  
Statistical Analysis 
 The comparison studies of column bed depth, column ion affinity, elution solvent, 
elution pH, and wash solvent included only a single replicate for each variable. For this 
reason statistical analyses of these data could not be performed. In order to determine 
which modification was better suited for the analysis of the target molecules, the peak 
area data for each analyte were imported into an Excel file and compared visually. The 
modification from each comparison study that produced the highest peak areas 
consistently was determined to be most effective. 
 Samples were extracted in triplicate and reconstituted with one of two different 
solvents for the reconstitution comparison study. Peak area data for both reconstitution 
solvents were imported to Excel. A log10 transformation was performed on the raw data 
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in order to alleviate departures from normality. T-tests for each analyte were performed 
using GraphPad Prism software (San Diego, CA). The p-value from each test was used to 
determine the statistical difference, if any, between the average peak areas produced by 
the two reconstitution solvents.   
Conclusion 
 Spiked urine samples were extracted by SPE and analyzed via LC-MS/MS. The 
final SPE method was determined to be the most effective procedure for extracting the 
synthetic cannabinoid analytes included in this method. The final method was determined 
by individually altering variables such as column depth and type; and wash, elution, and 
reconstitution solvents. The peak areas produced by the altered methods were then 
compared visually to determine which produced the best analysis for the target analytes. 
A statistical analysis was performed on the data gathered from the comparison of 
reconstitution solvents. The findings from all comparison studies were combined to 
determine the final method. Finally linearity, carryover, matrix effects, recovery 
efficiency, and process efficiency were determined for the final method.  
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CHAPTER IV 
 
 
RESULTS 
Column Bed and Elution Solvents 
 For most analytes there was little difference between the peak areas of the four 
extraction methods. As shown in Table 4, the DCM:IPA:FA (80:18:2) elutions had larger 
peak areas than the EtOAc:FA (98:2) elutions for the 500 ng/mL samples. Based on a 
visual comparison of the data, the performances of the 5 mg and 2.5 mg column beds 
were similar for the 500 ng/mL samples. When comparing the peak area data for all 
calibrator levels, no method consistently has larger peak areas for all analytes. However, 
the peak areas of the DCM:IPA:FA (80:18:2) elutions were larger more frequently than 
the EtOAc:FA (98:2) elution peak areas. 
THCA, THCA-D3, Δ9-THC, Δ9-THC-D3, and HU-210 were not successfully 
extracted for any of the four methods. JWH-250 5-Hydroxypentyl was not detected 
below 5 ng/mL, UR-144 was not detected below 50 ng/mL, UR-144 5-Hydroxypentyl 
metabolite was not detected below 10 ng/mL, and XLR-11 was not detected below 10 
ng/mL for any of the extraction methods. 
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Table	4.	Peak	areas	for	of	500	ng/mL	analytes	for	the	comparison	of	5	mm	and	2.5	mm	
column	bed	depths,	and	ethyl	acetate	and	dichloromethane	elution	solvents.	The	highest	
peak	area	ratio	for	each	analyte	is	indicate	with	bold	font,	and	"-----"	indicates	that	no	peak	
was	detected.	
Analyte	
5	mm	
Column,	
EtOAc	
Elution	
2.5	mm	
Column,	
EtOAc	
Elution	
5	mm	
Column,	
DCM	
Elution	
2.5	mm	
Column,	
DCM	
Elution	
5-Fluoro	PB-22	 3.32E+07	 4.08E+07	 4.39E+07	 4.57E+07	
AB-FUBINACA	 1.29E+06	 2.35E+06	 2.18E+06	 2.17E+06	
AM2201	4-Hydroxypentyl	metabolite	 8.40E+06	 9.03E+06	 9.52E+06	 9.73E+06	
HU-210	 -----	 -----	 -----	 -----	
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 6.36E+05	 8.07E+05	 9.46E+05	 9.06E+05	
IS	JWH-018	Metabolite-D5	 1.90E+05	 2.38E+05	 2.82E+05	 2.88E+05	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 1.11E+06	 1.35E+06	 1.59E+06	 1.61E+06	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 4.58E+05	 6.61E+05	 7.91E+05	 6.56E+05	
IS	THC-D3	 -----	 -----	 -----	 -----	
IS	THCA-D3	 -----	 -----	 -----	 -----	
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 6.07E+05	 7.81E+05	 1.02E+06	 8.73E+05	
JWH-018	Metabolite	 1.04E+07	 1.61E+07	 1.63E+07	 1.62E+07	
JWH-019	5-Hydroxyheyxyl	metabolite	 9.75E+06	 1.09E+07	 1.26E+07	 1.25E+07	
JWH-073	Metabolite	 1.41E+07	 1.77E+07	 1.94E+07	 1.88E+07	
JWH-122	5-Hydroxypentyl	metabolite	 7.03E+06	 1.16E+07	 1.19E+07	 1.25E+07	
JWH-250	5-Hydroxypentyl	 6.24E+06	 6.45E+06	 7.63E+06	 6.72E+06	
PB-22	 2.97E+07	 4.01E+07	 3.93E+07	 4.06E+07	
THC	 -----	 -----	 -----	 -----	
THCA	 -----	 -----	 -----	 -----	
UR-144	 1.67E+06	 1.95E+06	 1.55E+06	 1.60E+06	
UR-144	5-Hydroxypentyl	metabolite	 5.05E+06	 7.27E+06	 8.25E+06	 7.73E+06	
XLR-11	 6.26E+06	 7.05E+06	 7.29E+06	 7.39E+06	
XLR-11	4-Hydroxypentyl	metabolite	 4.56E+06	 4.34E+06	 5.71E+06	 4.61E+06	
 
Water to Methanol Ratio in Wash 
 The unsuccessful extraction of THCA, THCA-D3, Δ9-THC, Δ9-THC-D3, and 
HU-210 in the previous study was thought to be a result of the high methanol content of 
the second wash in the SPEware SPE method. In attempt to recover the lost analytes, one 
set of 500 ng/mL urine samples was extracted and washed with the recommended 70% 
MeOH wash, one set was washed with less methanol (30% MeOH), and a third set was 
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washed without methanol. The analyte peak areas from the 5 mg column extractions are 
shown in Table 5, and the peak areas from the 2.5 mg column extractions are shown in 
Table 6. 
 
 
 
 
Table	5.	Peak	areas	for	the	effect	of	methanol	content	of	the	second	wash	on	analyte	
extraction	for	5	mg	column	bed.	"-----"	indicates	that	no	peak	was	detected.	
Analyte	 70%	MeOH	 30%	MeOH	 100%	H2O	
5-Fluoro	PB-22	 2.98E+07	 7.55E+07	 6.06E+07	
AB-FUBINACA	 1.72E+06	 1.13E+07	 1.94E+07	
AM2201	4-Hydroxypentyl	metabolite	 6.27E+06	 5.36E+07	 3.68E+07	
HU-210	 -----	 ----- ----- 
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 3.59E+05	 2.71E+06	 2.51E+06	
IS	JWH-018	Metabolite-D5	 1.28E+05	 1.46E+06	 7.17E+05	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 4.98E+05	 4.61E+06	 2.44E+06	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 2.44E+05	 2.88E+06	 4.91E+06	
IS	THC-D3	 -----	 ----- ----- 
IS	THCA-D3	 -----	 ----- ----- 
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 5.21E+05	 3.96E+06	 4.00E+06	
JWH-018	Metabolite	 1.06E+07	 5.67E+07	 4.96E+07	
JWH-019	5-Hydroxyheyxyl	metabolite	 8.21E+06	 5.28E+07	 3.86E+07	
JWH-073	Metabolite	 9.43E+06	 6.36E+07	 5.26E+07	
JWH-122	5-Hydroxypentyl	metabolite	 8.03E+06	 4.81E+07	 2.96E+07	
JWH-250	5-Hydroxypentyl	 3.95E+06	 5.28E+07	 5.41E+07	
PB-22	 2.89E+07	 5.00E+07	 3.86E+07	
THC	 -----	 ----- ----- 
THCA	 -----	 ----- ----- 
UR-144	 1.10E+06	 1.25E+06	 1.18E+06	
UR-144	5-Hydroxypentyl	metabolite	 4.77E+06	 3.13E+07	 4.51E+07	
XLR-11	 5.51E+06	 1.10E+07	 9.60E+06	
XLR-11	4-Hydroxypentyl	metabolite	 2.70E+06	 2.24E+07	 2.71E+07	
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 Decreasing the methanol content of the second wash step did not improve the 
extraction and detection of THCA, THCA-D3, Δ9-THC, Δ9-THC-D3, or HU-210. 
However, the peak areas for all other analytes were greatly increased when less methanol 
was used in the second wash step. These results indicated that the high methanol content 
(70% MeOH) of the recommended wash step resulted in the loss of synthetic cannabinoid 
analyte during the extraction process. Based on these results, the SPEware SPE method 
was determined to be inappropriate for the extraction of the analytes of interest in this 
study due to high methanol concentration in the second wash step. Further analyses were 
Table	6.	Peak	areas	for	effects	of	methanol	content	of	the	second	wash	on	analyte	extraction	
for	2.5	mg	column	bed.	"-----"	indicates	that	no	peak	was	detected.	
Analyte	 70%	MeOH	 30%	MeOH	 100%	H2O	
5-Fluoro	PB-22	 3.70E+07	 7.52E+07	 6.77E+07	
AB-FUBINACA	 2.29E+06	 7.03E+06	 1.32E+07	
AM2201	4-Hydroxypentyl	metabolite	 9.10E+06	 5.03E+07	 3.93E+07	
HU-210	 -----	 ----- ----- 
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 3.71E+05	 2.35E+06	 2.62E+06	
IS	JWH-018	Metabolite-D5	 1.91E+05	 1.19E+06	 7.75E+05	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 7.70E+05	 4.25E+06	 3.23E+06	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 3.06E+05	 1.29E+06	 3.11E+06	
IS	THC-D3	 -----	 ----- ----- 
IS	THCA-D3	 -----	 ----- ----- 
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 7.25E+05	 2.27E+06	 2.84E+06	
JWH-018	Metabolite	 1.04E+07	 5.41E+07	 5.14E+07	
JWH-019	5-Hydroxyheyxyl	metabolite	 1.25E+07	 5.21E+07	 5.01E+07	
JWH-073	Metabolite	 9.87E+06	 5.75E+07	 5.12E+07	
JWH-122	5-Hydroxypentyl	metabolite	 8.06E+06	 4.83E+07	 4.01E+07	
JWH-250	5-Hydroxypentyl	 6.37E+06	 3.37E+07	 4.01E+07	
PB-22	 4.08E+07	 5.30E+07	 5.04E+07	
THC	 -----	 ----- ----- 
THCA	 -----	 ----- ----- 
UR-144	 1.51E+06	 1.64E+06	 1.12E+06	
UR-144	5-Hydroxypentyl	metabolite	 4.52E+06	 1.65E+07	 3.49E+07	
XLR-11	 8.18E+06	 1.22E+07	 1.14E+07	
XLR-11	4-Hydroxypentyl	metabolite	 3.99E+06	 1.38E+07	 1.82E+07	
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completed by following the FTTL SPE method which had no methanol in any of the 
three wash solutions.  
Column Ion Affinity and Eluent pH 
 The FTTL SPE method was previously shown to successfully extract THCA, JWH-018 
metabolite, and JWH-073 metabolite with a cation exchange column, (CEREX® HP SCX 5 mg 
NBE column), and a basic eluent consisting of DCM:IPA:NH4OH (80:18:2). Previous analyses 
during this study were competed with anion exchange columns, (CEREX® HP SAX 5 mg and 
2.5 mm NBE columns), and acid eluents containing 2% formic acid.  
In order to determine which column type and eluent pH combination was most effective 
for the extraction of the analytes in this study, four 500 ng/mL samples were extracted following 
the SPEware sample preparation procedure and the FTTL SPE procedure. The first sample was 
extracted with a HP SAX column paired with an acidic DCM:IPA:FA (80:18:2) eluent. A second 
sample was extracted with the HP SCX and the acidic DCM:IPA:FA (80:18:2) eluent. The HP 
SAX and HP SCX column were then used for the third and fourth samples respectively, and 
paired with a basic DCM:IPA:NH4OH eluent. The same four extractions were then repeated using 
the FTTL sample preparation procedure.    
The peak areas for the samples prepared by the SPEware procedure are shown in Table 7. 
The HP SCX with FA eluent and HP SAX with NH4OH eluent produced the highest peak areas 
for most analytes. From these data it was determined that acid eluents are better for the recovery 
of synthetic cannabinoids from cation exchange columns, while basic eluents are better for the 
recovery of synthetic cannabinoids from anion exchange columns.  
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  The peak areas for the samples prepared via the FTTL procedure are shown in Table 8. 
The HP SAX column paired with the basic NH4OH eluent produced the highest peak area for 
most analytes. Overall for the two sample preparation methods, the FTTL preparation with the 
HP SAX column and DCM:IPA:NH4OH elution performed best. The HP SCX column with either 
eluent produced higher peak areas for THCA, however the increase in peak area was minimal, 
and the HP SAX column showed better recovery of HU-210. A higher peak area for HU-210 and 
the other synthetic cannabinoids was given priority over the higher peak area of THCA for this 
Table	7.	Peak	areas	for	analysis	of	the	effect	of	the	column	ion	affinity	and	acid	or	basic	
elution	on	the	extraction	of	synthetic	cannabinoids.	Samples	prepared	via	the	SPEware	SPE	
method	sample	preparation	procedure.	The	largest	peak	area	for	each	column/elution	
combination	is	indicated	with	bold	font.	
Analyte	
HP	SAX	
DCM:IPA:
FA	
HP	SCX	
DCM:IPA:
FA	
HP	SAX	
DCM:IPA:
NH4OH	
HP	SCX	
DCM:IPA:
NH4OH	
5-Fluoro	PB-22	 3.36E+07	 5.24E+07	 4.94E+07	 6.54E+07	
AB-FUBINACA	 1.85E+07	 4.83E+07	 4.76E+07	 4.53E+07	
AM2201	4-Hydroxypentyl	metabolite	 2.04E+07	 4.54E+07	 6.52E+07	 4.57E+07	
HU-210	 1.23E+04	 6.09E+04	 2.78E+05	 1.04E+04	
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 9.95E+05	 3.43E+06	 2.36E+06	 2.43E+06	
IS	JWH-018	Metabolite-D5	 5.06E+05	 9.36E+05	 1.25E+06	 8.28E+05	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 1.69E+06	 4.77E+06	 5.64E+06	 3.49E+06	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 2.31E+06	 8.93E+06	 2.20E+06	 7.23E+06	
IS	THC-D3	 4.10E+03	 8.38E+04	 1.83E+05	 5.58E+03	
IS	THCA-D3	 7.53E+03	 1.00E+04	 4.98E+03	 5.86E+03	
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 3.22E+06	 6.70E+06	 7.65E+06	 6.32E+06	
JWH-018	Metabolite	 2.54E+07	 5.69E+07	 5.95E+07	 5.56E+07	
JWH-019	5-Hydroxyheyxyl	metabolite	 2.46E+07	 5.60E+07	 5.14E+07	 5.01E+07	
JWH-073	Metabolite	 2.40E+07	 5.41E+07	 5.73E+07	 5.27E+07	
JWH-122	5-Hydroxypentyl	metabolite	 1.26E+07	 4.11E+07	 4.27E+07	 2.77E+07	
JWH-250	5-Hydroxypentyl	 3.85E+07	 6.48E+07	 4.55E+07	 5.83E+07	
PB-22	 2.40E+07	 3.19E+07	 5.18E+07	 3.98E+07	
THC	 4.19E+03	 6.65E+04	 1.27E+05	 5.57E+03	
THCA	 5.76E+03	 1.43E+04	 9.28E+03	 7.47E+03	
UR-144	 9.23E+05	 9.48E+06	 1.50E+07	 1.10E+06	
UR-144	5-Hydroxypentyl	metabolite	 2.12E+07	 5.33E+07	 5.54E+07	 5.31E+07	
XLR-11	 6.25E+06	 1.74E+07	 2.27E+07	 7.97E+06	
XLR-11	4-Hydroxypentyl	metabolite	 1.58E+07	 4.01E+07	 3.96E+07	 4.34E+07	
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method. Therefore, the FTTL sample preparation with the HP SAX column and 
DCM:IPA:NH4OH elution was determined to be the best method for the extraction of the 
synthetic cannabinoid analytes included in this study.   
Reconstitution Solvent 
 The last adjustment to the SPE method was the content of the reconstitution solvent. All 
previous samples were reconstituted with 100 µL of 9:1 MPA:MPB, which is 10% acetonitrile in 
water. However, the FTTL SPE procedure was previously shown to successfully extract THCA, 
Table	8.	Peak	areas	for	analysis	of	the	effect	of	the	column	ion	affinity	and	acid	or	basic	
elution	on	the	extraction	of	synthetic	cannabinoids.	Samples	prepared	via	the	FTTL	SPE	
method	sample	preparation	procedure.	The	largest	peak	area	for	each	column/elution	
combination	is	indicated	with	bold	font.	
Analyte	
HP	SAX	
DCM:IPA:
FA	
HP	SCX	
DCM:IPA:
FA	
HP	SAX	
DCM:IPA:
NH4OH	
HP	SCX	
DCM:IPA:
NH4OH	
5-Fluoro	PB-22	 3.70E+07	 4.83E+04	 7.09E+07	 4.76E+07	
AB-FUBINACA	 4.23E+07	 3.70E+07	 5.76E+07	 3.75E+07	
AM2201	4-Hydroxypentyl	metabolite	 4.00E+07	 3.13E+07	 5.37E+07	 3.16E+07	
HU-210	 2.14E+04	 2.50E+04	 2.76E+05	 6.08E+03	
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 1.84E+06	 1.55E+06	 3.33E+06	 1.30E+06	
IS	JWH-018	Metabolite-D5	 6.77E+05	 5.34E+05	 1.40E+06	 6.98E+05	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 2.63E+06	 2.14E+06	 6.69E+06	 2.24E+06	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 2.52E+06	 4.42E+06	 3.94E+06	 3.87E+06	
IS	THC-D3	 9.87E+03	 1.34E+04	 6.62E+04	 2.05E+03	
IS	THCA-D3	 3.20E+03	 4.99E+03	 3.89E+03	 3.26E+03	
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 4.47E+06	 3.36E+06	 9.20E+06	 4.79E+06	
JWH-018	Metabolite	 4.22E+07	 3.39E+07	 6.76E+07	 3.76E+07	
JWH-019	5-Hydroxyheyxyl	metabolite	 4.27E+07	 3.36E+07	 5.96E+07	 3.95E+07	
JWH-073	Metabolite	 5.07E+07	 4.28E+07	 6.26E+07	 3.84E+07	
JWH-122	5-Hydroxypentyl	metabolite	 1.87E+07	 1.36E+07	 5.41E+07	 1.85E+07	
JWH-250	5-Hydroxypentyl	 4.75E+07	 4.74E+07	 5.72E+07	 5.12E+07	
PB-22	 2.24E+07	 7.92E+04	 6.07E+07	 1.83E+07	
THC	 1.58E+04	 2.18E+04	 8.81E+04	 2.57E+03	
THCA	 1.08E+04	 1.33E+04	 7.02E+03	 6.15E+03	
UR-144	 1.72E+06	 2.35E+06	 8.52E+06	 4.32E+05	
UR-144	5-Hydroxypentyl	metabolite	 3.79E+07	 2.83E+07	 6.48E+07	 3.74E+07	
XLR-11	 6.71E+06	 6.82E+06	 1.70E+07	 3.85E+06	
XLR-11	4-Hydroxypentyl	metabolite	 3.96E+07	 3.47E+07	 4.83E+07	 2.82E+07	
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JWH-018 metabolite, and JWH-073 metabolite in clinical urine samples by reconstituting with 
100 µL of 20% MeOH. In addition, the data from the analysis of the MeOH content of SPE wash 
solutions indicated that synthetic cannabinoids are easily displaced off the SPE column by 
methanol. Therefore, a 20% MeOH reconstitution solvent may increase the recovery of dried 
analytes.    
 Six samples were extracted following the same procedure; three samples were 
reconstituted with 100 µL of MPA:MPB (9:1), and three were reconstituted with 100 µL of 
20% MeOH. The three peak areas for each reconstitution step were averaged and the standard 
deviation was calculated. The first sample for the 20% MeOH reconstitution had much lower 
peak areas than the other two samples. This indicated that there may have been a bad injection on 
the instrument or a mistake during the extraction. The inaccurate data were substituted with a data 
from a 20% MeOH reconstitution sample run at a later date.  
 The average peak areas for the log10 transformed data, relative standard deviations, and 
p-values of the t-tests for all analytes are shown in Table 9.  At an alpha value of 0.1 – 0.05, there 
is a significant difference in analyte recovery between the two reconstitution methods for 
AM2201 metabolite and AM2201 D-5, UR-144 metabolite, and XLR-11. At and alpha value of 
0.05 – 0.01, the average peak area ratios were significantly higher with the 20% MeOH 
reconstitution for 5-fluoro PB-22, JWH-018 and JWH-018 D-5, UR-144 metabolite D-5, and 
JWH-019 metabolite,JWH-073 metabolite, JWH-122 metabolite, and JWH-250 metabolite. These 
results indicate that a methanol based reconstitution provides better recovery of synthetic 
cannabinoids than an acetonitrile based reconstitution.  
 However, there was still not good recovery of THCA or THCA-D3 with either 
reconstitution method. Two 500 ng/mL THCA samples were extracted and reconstituted with 
each reconstitution solution. The data for the two THCA samples are shown in Table 10. The 
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detection of THCA still not sufficiently improved when potential interference from other analytes 
were removed. Based on these data, the method was determined to be insufficiently sensitive for 
the detection of THCA. THCA and THCA-D3 were not included in the final method.  
Table	9.	Average	peak	area	and	standard	deviation	of	samples	reconstituted	with	9:1	MPA:MPB	
and	20%	MeOH.	Standard	deviations	are	reported	as	percent	standard	deviation	relative	to	the	
mean.	†Calculated	with	a	fourth	sample	substituted	for	the	first	sample.	*Denotes	statistical	
difference	at	alpha	0.1	–	0.05.	**Denotes	statistical	difference	at	alpha	0.05	–	0.01.		
Analyte	
Average	
MPA:MPB	 RSD	
†Average	
20%	MeOH	 RSD	 p-value	
5-Fluoro	PB-22	 7.9	 0.7%	 8.0	 0.3%	 0.03**	
AB-FUBINACA	 7.7	 0.6%	 7.7	 0.7%	 0.25	
AM2201	4-Hydroxypentyl	metabolite	 7.7	 1.2%	 7.8	 0.3%	 0.09*	
HU-210	 5.6	 7.6%	 5.8	 1.4%	 0.33	
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 6.5	 1.2%	 6.6	 0.4%	 0.06*	
IS	JWH-018	Metabolite-D5	 6.1	 1.5%	 6.3	 0.8%	 0.04**	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 6.9	 1.6%	 7.0	 0.9%	 0.12	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 6.4	 1.9%	 6.7	 0.5%	 0.02**	
IS	THC-D3	 5.0	 4.4%	 5.3	 4.7%	 0.26	
IS	THCA-D3	 3.9	 2.7%	 4.1	 3.0%	 0.16	
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 6.9	 1.3%	 7.1	 0.3%	 0.03**	
JWH-018	Metabolite	 7.8	 0.2%	 7.9	 0.1%	 0.01**	
JWH-019	5-Hydroxyheyxyl	metabolite	 7.8	 0.3%	 7.9	 0.1%	 0.01**	
JWH-073	Metabolite	 7.8	 0.3%	 7.9	 0.2%	 0.03**	
JWH-122	5-Hydroxypentyl	metabolite	 7.8	 0.3%	 7.9	 0.2%	 0.02**	
JWH-250	5-Hydroxypentyl	 7.7	 0.5%	 7.8	 0.3%	 0.02**	
PB-22	 7.8	 1.1%	 7.9	 0.8%	 0.21	
THC	 5.1	 4.2%	 5.4	 4.6%	 0.29	
THCA	 4.0	 3.2%	 4.1	 5.4%	 0.33	
UR-144	 7.1	 3.2%	 7.3	 4.7%	 0.36	
UR-144	5-Hydroxypentyl	metabolite	 7.8	 0.3%	 7.8	 0.1%	 0.06*	
XLR-11	 7.5	 1.4%	 7.7	 1.2%	 0.05*	
XLR-11	4-Hydroxypentyl	metabolite	 7.7	 0.3%	 7.7	 0.2%	 0.02**	
 
Table	10.	Peak	areas	of	the	500	ng/mL	THCA	samples	
reconstituted	with	9:1	MPA:MPB	and	20%	MeOH.	
Analyte	 9:1	MPA:MPB	 20%	MeOH	
THCA	 24,035	 22,146	
IS	THC-D3	 30,467	 25,348	
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Linearity and Carryover 
 Linearity and carryover studies were performed on the final method. For the linearity 
study six calibration curves were extracted and analyzed. Each calibration curve consisted of a 1c 
at the concentration of the Lower limit of quantitation (LLOQ), 2c, 5c, 10c, 15c, and 25c at the 
Upper limit of quantitation (ULOQ). Except for the Δ9-THC calibration curve, which had 
consisted of a 2c at the concentration of the LLOQ, 5c, 10c, 15c, and 25c at the ULOQ. Table 11 
provides the LLOQ, ULOQ, calibration fit, and weighting for each analyte.  
Table	11.	Lower	limit	of	quantitation	(LLOQ),	Upper	limit	of	quantitation	(ULOQ),	calibration	
curve	fit	type,	and	weighting	used	for	each	analyte.	
Analyte	 LLOQ	 ULOQ	 FIT	TYPE	 WEIGHT	
5-Fluoro	PB-22	 1	 25	 Quadratic	 1/C^2	
AB-FUBINACA	 1	 25	 Linear	 1/C^2	
AM2201	4-Hydroxypentyl	metabolite	 1	 25	 Linear	 1/C	
HU-210	 400	 5000	 Quadratic	 1/C	
JWH-018	Metabolite	 1	 25	 Quadratic	 1/C^2	
JWH-019	5-Hydroxyheyxyl	metabolite	 1	 25	 Linear	 1/C^2	
JWH-073	Metabolite	 1	 25	 Linear	 1/C^2	
JWH-122	5-Hydroxypentyl	metabolite	 1	 25	 Quadratic	 1/C^2	
JWH-250	5-Hydroxypentyl	 2	 50	 Linear	 1/C^2	
PB-22	 1	 25	 Quadratic	 1/C^2	
THC	 200	 2500	 Linear	 None	
UR-144	 2	 50	 Quadratic	 1/C^2	
UR-144	5-Hydroxypentyl	metabolite	 2	 50	 Linear	 1/C	
XLR-11	 2	 50	 Quadratic	 1/C	
XLR-11	4-Hydroxypentyl	metabolite	 2	 50	 Linear	 1/C^2	
 
 Blank urine samples were extracted and analyzed after the highest concentration 
calibrator to access the carryover for all analytes in the method. No peaks were detected above 
the LLOQ for any analytes at the 25c level. The method was determined to have no carryover 
within the quantitation range.  
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Matrix Effects 
 Five samples each of neat, pre-extraction spike, and post-extraction spike samples were 
analyzed to determine the Matrix Effects (ME), Recovery Efficiency (RE), and Process 
Efficiency (PE) of each analyte. The ME values provides a measure of ion suppression and 
enhancement. Values should ideally be within 40% of the target concentration. RE measures the 
efficiency of analyte recovery of the extraction method. Ideally the RE will be greater than 50%. 
PE measures the measures the efficiency of analyte detection on the instrument. RE and PE 
values less than 50% may be acceptable if the method is sufficiently selective and sensitive 
enough to produce forensically or medically relevant results. The ME, RE, and PE values for all 
analytes are shown in Table 11. 
 There is not significant ion suppression for any analytes, but 5-Fluoro PB-22, PB-22, and 
HU-210 all have significant ion enhancement. The enhancement is most likely caused by the 
other analytes within the method. Therefore, chromatography must be adjust before these three 
analytes can pass validation. The REs of 5-Fluoro PB-22 and PB-22 are 25% and 17%, 
respectively, which is far below the lowest ideal value of 50%. HU-210 also has significantly 
high values for RE (158%) and PE (417%). The REs and PEs of UR-144 and XLR-11 are also 
below 50%.  
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Table	12.	Matrix	effects	(ME),	Recovery	efficiency	(RE),	and	Process	efficiency	(PE)	for	all	
analytes.	ME	values	with	bold	font	indicate	ion	suppression	or	enhancement	greater	than	or	
less	than	40%.	RE	and	PE	values	with	bold	font	indicate	less	than	50%	efficiency.	
Analyte	
Matrix	Effects	
(ME)	
Recovery	
Efficiency	(RE)	
Process	
Efficiency	(PE)	
5-Fluoro	PB-22	 242%	 25%	 60%	
AB-FUBINACA	 75%	 143%	 107%	
AM2201	4-Hydroxypentyl	metabolite	 110%	 59%	 65%	
HU-210	 265%	 158%	 417%	
JWH-018	Metabolite	 74%	 91%	 68%	
JWH-019	5-Hydroxyheyxyl	metabolite	 87%	 77%	 67%	
JWH-073	Metabolite	 79%	 83%	 66%	
JWH-122	5-Hydroxypentyl	metabolite	 121%	 61%	 74%	
JWH-250	5-Hydroxypentyl	 99%	 67%	 67%	
PB-22	 270%	 17%	 46%	
THC	 104%	 79%	 82%	
UR-144	 108%	 12%	 12%	
UR-144	5-Hydroxypentyl	metabolite	 74%	 78%	 58%	
XLR-11	 64%	 29%	 19%	
XLR-11	4-Hydroxypentyl	metabolite	 98%	 82%	 80%	
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CHAPTER V 
 
 
CONCLUSION 
 The purpose of this study was to provide an improved extraction and detection method 
for synthetic cannabinoids in urine. An additionally goal was to successfully detect a natural 
cannabinoid, Δ9-THC, and its metabolite, THCA. The final method included 10 synthetic 
cannabinoid metabolites, 4 synthetic cannabinoid parent drugs, and Δ9-THC. All of the synthetic 
cannabinoids included in the method are currently controlled by the Drug Enforcement Agency as 
Schedule I controlled substances.34   
 The size of the column bed did not make a much impact on the extraction of synthetic 
cannabinoids. The data from the first comparison study show little difference in the peak areas of 
the 5 mg and 2.5 mg columns. However, the first study did show that eluent polarity impacts the 
elution of synthetic cannabinoids. The dichloromethane elution peak areas were consistently lager 
than the peak areas of the ethyl acetate elutions.  
 The comparison study of the methanol content in SPE washes showed that synthetic 
cannabinoids are partially eluted off the SPE column by high concentrations of methanol. The 
70% MeOH washed samples showed notably lower peak areas than the samples washed with 
little or no methanol. These data indicate that methanol should not be included in any wash step 
for the SPE extraction of synthetic cannabinoids.  
 The synthetic cannabinoids in this study were best extracted with a anion exchanging 
column (HP SAX) paired with a basic eluent (DCM:IPANH4OH 80:18:2). The best results for 
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HP SAX and DCM:IPA:NH4OH combination were achieved when using 350 µL of 0.3 M 
sodium acetate buffer (pH 4.8) during the sample preparation according to the FTTL 
procedure. The THCA peak areas were largest with a cation exchanging column (HP 
SCX) paired with an acidic eluent (DCM:IPA:FA 80:18:2). If including THCA in the 
synthetic cannabinoid method was high priority, the HP SCX and DCM:IPA:FA elution 
would be the most favorable column/eluent combination.  
 The final comparison study showed that reconstituting the dried samples with 
20% MeOH had significantly higher peak areas than the samples reconstructed with an 
acetonitrile solutions (MPA:MPA 9:1) for 4 analytes at an alpha of 0.1 – 0,05 and 10 
analytes at an alpha of 0.05 – 0.01. The increase in peak area indicates that the synthetic 
cannabinoids are more soluble in methanol than acetonitrile.  
 Validation studies performed on the final method showed no analyte carryover at 
the 25c calibrator. The linearity study showed that while some analytes fit a linear 
calibration model, other were better fit with a quadratic calibration model. Matrix effects 
studies showed no major ion suppression, but significant ion enhancement was present 
for HU-210, 5-Fluoro PB-22, and PB-22. The ion enhancement of these drugs must be 
addressed and corrected before further validation can occur. PB-22, 5-Fluoro PB-22, UR-
144, and XLR-11 had recovery efficiencies below the minimum desired value of 50%. 
PB-22, UR-144, and XLR-11 had process efficiency values below the minimum desired 
value of 50%. However, recovery and process efficiencies below 50% are acceptable as 
long as the method is sufficiently sensitive enough to provide medically or forensically 
relevant results.  
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 The information gained during the comparison studies enabled the improvement 
of existing SPE methods for the extraction of synthetic cannabinoids from urine. With the 
original SPE extraction method, THC, HU-210, and THCA could not be detected at or 
below 500 ng/mL. With the improved method, THC and HU-210 were detectable down 
to 200 ng/mL and 400 ng/mL respectively, and although THCA was not included in the 
final method it was detectable at 500 ng/mL. The peak areas were greatly increased for 
all synthetic cannabinoids included in this study. The knowledge gained during this study 
can be applied to the continued improvement of synthetic cannabinoid detection and the 
inclusion of more synthetic cannabinoids in the existing method.     
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APPENDICES 
 
 
A1.	Data	for	the	three	replicates	of	the	9:1	MPA:MPB	reconstitution	gathered	during	the	
reconstitution	solvent	comparison	study	
Analyte	 Sample	1	 Sample	2	 Sample	3	
5-Fluoro	PB-22	 6.31E+07	 7.66E+07	 7.99E+07	
AB-FUBINACA	 4.74E+07	 4.58E+07	 5.55E+07	
AM2201	4-Hydroxypentyl	metabolite	 3.83E+07	 5.14E+07	 5.76E+07	
HU-210	 1.19E+05	 6.98E+05	 5.94E+05	
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 3.40E+06	 2.60E+06	 3.70E+06	
IS	JWH-018	Metabolite-D5	 1.28E+06	 1.21E+06	 1.79E+06	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 6.14E+06	 6.53E+06	 9.76E+06	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 3.06E+06	 1.98E+06	 3.33E+06	
IS	THC-D3	 6.12E+04	 1.47E+05	 1.50E+05	
IS	THCA-D3	 6.33E+03	 9.21E+03	 1.00E+04	
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 7.21E+06	 6.96E+06	 1.02E+07	
JWH-018	Metabolite	 6.61E+07	 6.60E+07	 7.07E+07	
JWH-019	5-Hydroxyheyxyl	metabolite	 6.21E+07	 5.79E+07	 6.50E+07	
JWH-073	Metabolite	 6.22E+07	 6.08E+07	 6.80E+07	
JWH-122	5-Hydroxypentyl	metabolite	 5.97E+07	 5.93E+07	 6.55E+07	
JWH-250	5-Hydroxypentyl	 5.18E+07	 4.71E+07	 5.58E+07	
PB-22	 5.39E+07	 7.50E+07	 7.79E+07	
THC	 7.68E+04	 1.76E+05	 1.88E+05	
THCA	 7.08E+03	 8.90E+03	 1.27E+04	
UR-144	 6.78E+06	 1.71E+07	 1.61E+07	
UR-144	5-Hydroxypentyl	metabolite	 5.90E+07	 5.85E+07	 6.51E+07	
XLR-11	 2.14E+07	 3.14E+07	 3.36E+07	
XLR-11	4-Hydroxypentyl	metabolite	 4.44E+07	 4.23E+07	 4.78E+07	
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A2.	Data	for	the	three	replicates	of	the	20%	methanol	reconstitution	gathered	during	the	
reconstitution	solvent	comparison	study	
Analyte	 Sample	1	 Sample	2	 Sample	3	
5-Fluoro	PB-22	 9.04E+07	 9.21E+07	 1.01E+08	
AB-FUBINACA	 5.87E+07	 6.14E+07	 4.86E+07	
AM2201	4-Hydroxypentyl	metabolite	 6.05E+07	 6.56E+07	 6.61E+07	
HU-210	 6.78E+05	 5.79E+05	 8.46E+05	
IS	AM2201	4-Hydroxypentyl	metabolite	D5	 4.08E+06	 4.63E+06	 4.19E+06	
IS	JWH-018	Metabolite-D5	 2.02E+06	 1.92E+06	 2.38E+06	
IS	JWH-122	4-Hydroxypentyl	metabolite	D5	 1.08E+07	 8.60E+06	 1.14E+07	
IS	JWH-250	4-Hydroxypentyl	metabolite	D5	 4.53E+06	 5.08E+06	 5.16E+06	
IS	THC-D3	 1.37E+05	 1.47E+05	 3.80E+05	
IS	THCA-D3	 8.86E+03	 1.35E+04	 1.50E+04	
IS	UR-144	5-Hydroxypentyl	metabolite-D5	 1.16E+07	 1.15E+07	 1.27E+07	
JWH-018	Metabolite	 7.50E+07	 7.54E+07	 7.86E+07	
JWH-019	5-Hydroxyheyxyl	metabolite	 7.21E+07	 7.27E+07	 7.42E+07	
JWH-073	Metabolite	 7.10E+07	 7.66E+07	 7.25E+07	
JWH-122	5-Hydroxypentyl	metabolite	 7.35E+07	 6.88E+07	 7.02E+07	
JWH-250	5-Hydroxypentyl	 6.11E+07	 6.61E+07	 6.72E+07	
PB-22	 7.86E+07	 7.64E+07	 9.90E+07	
THC	 1.75E+05	 1.61E+05	 4.46E+05	
THCA	 1.39E+04	 2.28E+04	 8.08E+03	
UR-144	 1.52E+07	 1.26E+07	 5.35E+07	
UR-144	5-Hydroxypentyl	metabolite	 6.84E+07	 6.52E+07	 6.72E+07	
XLR-11	 4.30E+07	 4.06E+07	 5.92E+07	
XLR-11	4-Hydroxypentyl	metabolite	 4.98E+07	 5.31E+07	 5.24E+07	
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